Hold Strides Arcolab: Shahina Mukadam

Shahina Mukadam, market expert told CNBC-TV18, "I think one should hold on Strides Arcolab because while the stock has doubled in the last one year, there is short-term upside still left especially with the merger with Sashun Pharma, which is ongoing. However, with Shashun's multiples being lower than Strides the overall valuation will start looking better once the merger is fully implemented. Therefore, one can hold."

"One can add at lower levels but since the stock has run-up a bit one should wait for a correction may be closer to Rs 1,000-1,020-1,030 – a Rs 100 lower from here and one can add but this will be with a holding for about a year's timeline," she said.